Recently, the FDA officially approved Novartis's ribociclib, in combination with aromatase inhibitors (AI), for the adjuvant treatment of hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC)